Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Dapagliflozin / metformin price, strengths & recalls

Generic of Xigduo

Pharmacies pay $24.44 for 30 tablets of Dapagliflozin / metformin 10 mg / 1000 mg (24 hr) extended-release tablet this week, and from $14.61 to $24.44 across its 4 priced strengths and forms. 7 manufacturers make it. It has 2 recalls on record, none ongoing. Its official label last changed on April 10, 2026.

Generic
Pharmacies pay$24.44for 30 tablets of 10 mg / 1000 mg (24 hr) extended-release tablet+13.2% in 4 weeks
Fair cash price
$38.61
Strengths
4
Makers
7
Updated
Nov 11

Dapagliflozin / metformin price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
5 mg / 1000 mg (24 hr) extended-release tablet$0.4871$14.61 / 30 tablets+5.8%-91.7%
5 mg / 500 mg (24 hr) extended-release tablet$0.7060$21.18 / 30 tablets-0.2%
10 mg / 1000 mg (24 hr) extended-release tablet$0.8146$24.44 / 30 tablets+13.2%-93.1%
10 mg / 500 mg (24 hr) extended-release tablet$0.7588$22.76 / 30 tablets-5.4%

The lowest cost per tablet is 5 mg / 1000 mg (24 hr) extended-release tablet at $0.4871. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Brand names of dapagliflozin / metformin

A brand and its generic share the active ingredient; the generic is almost always far cheaper.

Supply status: shortages & recalls

No shortage reportedChecked Nov 17, 2026
No ongoing recalls2 recalls on record

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for dapagliflozin / metformin? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedApril 10, 2026
Version1
EffectiveApr 9, 2026
Read the label

These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HCL EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HCL EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014

This drug has a boxed warning

WARNING: LACTIC ACIDOSIS

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)].

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the full prescribing information [see Dosage and Administration (2.1 and 2.4), Contraindications (4),Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.6, 8.7)].

If metformin-associated lactic acidosis is suspected, immediately discontinue dapagliflozin and metformin HCl extended-release and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)].

WARNING: LACTIC ACIDOSIS

See full prescribing information for complete boxed warning.

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. (5.1)

Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. (5.1)

If lactic acidosis is suspected, discontinue dapagliflozin and metformin HCl extended-release and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)

Recent major changes (as listed on the label)

Indications and Usage (1) 12/2024

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA205649 · Astrazeneca Ab
First approved
October 29, 2014 (12 years ago)
Latest approved change
August 11, 2026
Approved label
PDF, Aug 18, 2026
Generic makers
6 approved generic applications on the market
Last patent listed
May 12, 2031
Exclusivity ends
December 12, 2027

Dapagliflozin / metformin questions

How much does dapagliflozin / metformin cost without insurance?

Pharmacies pay about $24.44 for 30 tablets of dapagliflozin / metformin 10 mg / 1000 mg (24 hr) extended-release tablet ($0.8146 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $38.61. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

What is the brand name of dapagliflozin / metformin?

Dapagliflozin / metformin is sold as Xigduo. The generic has the same active ingredient and usually costs far less.

Is dapagliflozin / metformin in shortage?

No shortage is reported for dapagliflozin / metformin right now. We check the national shortage list every day.

Has dapagliflozin / metformin been recalled?

2 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the dapagliflozin / metformin label last change?

The official label was last updated on April 10, 2026 (version 1). See what changed.

Talk about dapagliflozin / metformin

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.